Drug development biologies

Summary of a Workshop on Drug Development, Biological Diversity and Economic Growth held at the National Institutes of Health, Bethesda, Maryland, in March 1991.13... 

Tlie previous chapter traced the evolution of a biologically ac-I ive compound isolated from plant material—cocaine—into an extensive series of drugs by chemical dissection of that molecule. A-iiother frequently applied approach to drug development depends on I ho identification and study of the organic compounds that regu-l. ite most of the functions of mammalian organisms the hormones,... 

Despite great advances in the understanding of the biology of the parasite, progress in terms of drug development has been dreadfully slow. 

Clarke PA, te Poele R, Wooster R, Workman P (2001) Gene expression microarray analysis in cancer biology, pharmacology, and drug development progress and potential. Biochem Pharmacol 62 1311-1336... 

Biological activity is not the only criterion required for drug development, as anyone who has been involved in this area is aware. Potency, toxicity, bioavailability, metabolic stability, and plasma half-life are only a few of the critical issues that must be addressed. Although satisfactory potency and spectrum activity had been achieved with WIN54954, which has been clinically evaluated, this compound lacked metabolic stability and consequently displayed a short half-life. 

Considerable effort is often required to prepare sufficient quantities of key mammalian metabolites of drug candidates for biological activity evaluation or for use as analytical standards. The new regulatory guidance in drug development [5] will certainly lead to more emphasis on key human metabolite characterization. Microbial bioreactors can be used for... 

Cutler NR and Sramek JJ (2001). Review of the next generation of Alzheimer s disease therapeutics Challenges for drug development. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 25, 27-57. 

---